Exposure to Antiretrovirals (ARVs) and the Risk of Renal Impairment among HIV+ Persons with Normal Baseline Renal Function: the D:A:D Study

L Ryom1, A Mocroft2, SW Worm3, DA Kamara4, P Reiss5, M Ross6, C Fux7, P Morlat5, O Moranne8, C Smith9, O Kirk,10 and JD Lundgren1,0 on behalf of the D:A:D study group

1Copenhagen HIV Programme, University of Copenhagen, Copenhagen N, Denmark; 2Research Dept. of Infection and Population Health, UCL, London, UK; 3Academic Medical Center, Div. of Infectious Diseases and Dept. of Global Health, University of Amsterdam, The Netherlands; 4Division of Nephrology, Mount Sinai School of Medicine, New York, USA; 5Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Switzerland; 6Service de médecine interne et maladies infectieuses, Hôpital Saint-André, CHU de Bordeaux, France; 7Nephrology department, Public Health department, CHU Nice, France; 8Epidemiikkliniikan MS132, Righospitalet, Copenhagen, Denmark

BACKGROUND
Tenofivir (TDF), atazanavir (ATV) and other ARVs have been associated with renal impairment (ref. 1-5), but the extent of such adverse drug reactions in HIV+ persons with normal baseline renal function is unknown.

METHODS
D:A:D is a prospective cohort of 49,734 HIV+ persons from participating cohorts in Europe, USA and Australia. As of 2004 individuals in D:A:D with normal renal function defined as Cockcroft-Gault-estimated glomerular filtration rates (eGFR)=90 ml/min/1.73m² were followed to confirmed (at least 2 months apart) eGFR≤70 (ceGFR≤70); threshold below which protective ARV switches may occur; confirmed by eGFR<60 (CKD) or last eGFR. Discontinuation rates of individual ARVs according to latest eGFR were assessed. Poison regression models, adjusting for renal and HIV-related risk factors, were used to assess association with ceGFR≤70 and CKD.

RESULTS
Of 22,603 persons included with a normal baseline renal function 468 (2.1%) progressed to ceGFR≤70 (incidence rate (IR) 4.78/1000 PY [95%CI: 3.35-5.22]) and 131 (0.6%) to CKD [1.33/1000 PY (1.10-1.56)] during a median follow-up (FU) of 4.5 years (IQR 2.7-6.1). This eGFR decline of at least 20 ml/min (from eGFR=90 to ≤70) during 4.5 years equals an annual decline of at least 4-5 ml/min. Baseline characteristics of included persons are shown in Table 1.

Persons with eGFR levels between 60 and 70 had significantly higher rates of discontinuing TDF (adjusted IR ratio [aIRR] 1.72 [1.38-2.14]), but not of other ARVs tested, compared to persons with eGFR>90, Figure 2.

Cumulative TDF (aIRR 1.18 [1.12-1.25] per year) and ATV/r (1.19 [1.09-1.32]) were independently associated with increased rates of ceGFR≤70 from eGFR>90, but not with CKD, whereas lopinavir/r (LPV/r) use was associated with both endpoints [1.11 [1.05-1.17] and 1.22 [1.16-1.28] respectively, Figure 3]. Inconsistent trends were seen with abacavir use.

Analyses censoring for concomitant use of each of the ARVs were highly consistent.

SUMMARY
ARV exposure & rates of ceGFR≤70 from eGFR>90, Lopinavir/r

Table 1: Baseline characteristics of included persons

Limitations
Neither information on proteinuria nor familiar disposition to kidney disease is available within the study, and ethnicity information is restricted in some cohorts. Exposure to other potential nephrotoxic non-ARV drugs was not included. 4.5 years median FU may have been too limited to explore a drastic eGFR decline from levels >90 to CKD.

CONCLUSIONS
In HIV+ persons with normal baseline renal function, cumulative use of TDF, ATV/r and LPV/r were each associated with a fast eGFR decline, as were more traditional renal risk factors and HIV-related factors in adjusted models.

The rates of ARV associated deteriorations in renal function from normal function were low over the 4.5 years of FU available, but may represent significant issues for lifelong use should the rates remain constant or even increase with age. For instance after 5 years of TDF use the incidence rate of progression to ceGFR≤70 from levels >90 will be twice as high in TDF exposed compared to unexposed persons.

Increased discontinuation rates of TDF, but not of other ARVs in persons with decreasing eGFR suggest that drug switches are occurring more commonly for certain ARVs in relation to declining eGFR, and the switches may have prevented further deterioration to CKD. Closer monitoring of renal function may be appropriate for persons also on ATV/r and LPV/r.

References